Repros Therapeutics Inc. (RPRX) Reports First Quarter 2013 Financial Results
5/10/2013 9:19:56 AM
More...
|
Repros Therapeutics Inc. (RPRX) Reports Issuance of Two Additional U.S. Androxal® Patents
4/10/2013 11:11:37 AM
More...
|
Repros Therapeutics Inc. (RPRX) Testosterone Drug Hits Main Goals of Key Study
3/28/2013 7:28:05 AM
More...
|
Repros Therapeutics Inc. (RPRX) Release: American Urological Association (AUA) Accepts Androxal(R) Versus Topical Gel Comparative Study for Podium Presentation at Annual Meeting
3/25/2013 10:32:36 AM
More...
|
Repros Therapeutics Inc. (RPRX) Updates Guidance for Top Line Results From First Pivotal Androxal® Study to Q3 2013
1/28/2013 9:13:45 AM
More...
|
Repros Therapeutics Inc. (RPRX) Reports Core 1-Year DEXA Study Fully Enrolled Ahead of Schedule and Provides Update for Androxal® Clinical Program
1/7/2013 9:52:27 AM
More...
|
Repros Therapeutics Inc. (RPRX)' Proellex®-V Topline Analysis Suggests 12 Mg Dose Effective and Well Tolerated in Phase 2 for Uterine Fibroids
1/3/2013 8:52:37 AM
More...
|
Repros Therapeutics Inc. (RPRX) Reports Third Quarter 2012 Financial Results
11/14/2012 7:43:07 AM
More...
|
Repros Therapeutics Inc. (RPRX) Presents Androxal® and Proellex® Clinical Updates at the Lazard Capital Markets 9th Annual Healthcare Conference
11/14/2012 7:40:58 AM
More...
|
Repros Therapeutics Inc. (RPRX) to Present Androxal® and Proellex® Clinical Updates at the Lazard Capital Markets 9th Annual Healthcare Conference
11/5/2012 9:14:33 AM
More...
|
|